Dr. Peter M. Anderson

• 
  coms.publishpath.com/Rss.aspx?ContentID=282086 - [Cached Version]
  Published on: 9/12/2008    Last Visited: 10/2/2008  

  The film they are developing features the work of Dr. Pete Anderson, an osteosarcoma specialist, and his colleagues at the M. D. Anderson Cancer Center in Houston, Texas. (A ten minute clip from the film can be viewed by going to http://coms.ohiou.edu/stories-of-cancer-care).

• 
  www.biospace.com/news_story.aspx?NewsEntityId=96597&Sou - [Cached Version]
  Published on: 5/15/2008    Last Visited: 5/16/2008  

  "The results that we have seen to date from the Phase 3 clinical trial in patients with non-metastatic osteosarcoma are being supported in patients with lung metastases as the L-MTP-PE compassionate access experience continues to be encouraging," said Peter Anderson, M.D., Ph.D., principal investigator and professor of pediatrics, Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center in Houston.

• 
  phx.corporate-ir.net/phoenix.zhtml?c=97538&p=irol-newsA - [Cached Version]
  Published on: 9/18/2006    Last Visited: 3/17/2008  

  "The predominant pattern of treatment failure in AML involves incomplete elimination of the disease from the bone marrow," said Dr. Peter Anderson, a Pediatric Oncologist at The University of Texas MD Anderson Cancer Center, an investigator in the study and co-author of the publication.

• 
  www.rt-image.com/Room_to_Grow_PET_CT_for_pediatric_canc - [Cached Version]
  Published on: 6/13/2008    Last Visited: 6/13/2008  

  Peter Anderson, MD, PhD, a specialist in the field of solid tumors at the Children's Cancer Hospital at The University of Texas M. D. Anderson Cancer Center in Houston, first began to use PET/CT in the late 1990s while working at the Rochester, Minn.-based Mayo Clinic.
  
  The Children's Cancer Hospital at M. D. Anderson currently performs between 10 to 15 PET/CT procedures per week for pediatric cancer patients.It began to be used for pediatric patients in 2003.
  
  "PET/CT is phenomenally useful in certain situations for children with sarcomas, neuroblastomas, and lymphomas.You can tell whether patients are responding to chemotherapy and whether the disease is localized or not.Often, for patients with Hodgkin's disease, the positive results of a mass shrinking and good metabolic response shown on a PET/CT may be the first good news that you can give the family," Anderson says.
  
  He continues, "The images allow you to explain the disease process much better than with images from other modalities, particularly with respect to showing metastases.It is a great teaching tool."
  
  Anderson says that the images are also extremely useful for surgeons and radiotherapists to determine the site of local control.The PET/CT also helps justify when chemotherapy is no longer effective and surgery is necessary.
  
  Anderson also says that PET/CT is very useful in showing areas of the body that are hard to image, such as the mediastinum, and determining when a patient has metal in their body, such as after limb salvage, since metal often causes artifacts on CTs or MRIs.

• 
  phx.corporate-ir.net/phoenix.zhtml?c=97538&p=irol-newsA - [Cached Version]
  Published on: 6/8/2006    Last Visited: 8/7/2007  

  These study results indicate that samarium (Quadramet) could be a new treatment option for patients who would otherwise have a poor prognosis, "said Peter Anderson, M.D., Ph.D., a pediatric oncologist at Mayo Clinic.

• 
  www.biospace.com/news_story.aspx?NewsEntityId=75993 - [Cached Version]
  Published on: 11/2/2007    Last Visited: 11/2/2007  

  "These results are encouraging as there is a significant unmet treatment need for patients with osteosarcoma," said Dr. Peter Anderson, professor of pediatrics, The University of Texas M.D.Anderson Cancer Center in Houston.

• 
  phx.corporate-ir.net/phoenix.zhtml?c=97538&p=irol-newsA - [Cached Version]
  Published on: 8/7/2006    Last Visited: 8/7/2007  

  metastases and osteosarcoma" by Peter M. Anderson, M.D., Ph.D., a
  
  pediatric oncologist at The University of Texas MD Anderson Cancer

• 
  phx.corporate-ir.net/phoenix.zhtml?c=97538&p=irol-newsA - [Cached Version]
  Published on: 7/26/2006    Last Visited: 8/7/2007  

  The publication, "Samarium for osteoblastic bone metastases and osteosarcoma" by Pete Anderson, M.D., Ph.D., a Pediatric Oncologist at The University of Texas MD Anderson Cancer Center, appears in the August 2006 issue of the peer- reviewed journal Expert Opinion on Pharmacotherapy (Expert Opin.Pharmacother. (2006) 7(11):1475-1486).
  
  In the Expert Opinion section of the article, Dr Anderson wrote: "QUADRAMET is all too infrequently utilized as a means of palliation and based on emerging clinical data is likely a useful adjunct to improve response and durability of lesion control in combination with other therapeutic approaches.

• 
  phx.corporate-ir.net/phoenix.zhtml?c=97538&p=irol-newsA - [Cached Version]
  Published on: 4/5/2006    Last Visited: 8/7/2007  

  "Because it very specifically targets bone, QUADRAMET is ideally suited for treatment of a disease like osteosarcoma," said Pete Anderson, M.D., Ph.D., Professor with the University of Texas MD Anderson Cancer Center and one of the authors of the study.

• 
  phx.corporate-ir.net/phoenix.zhtml?c=97538&p=irol-newsA - [Cached Version]
  Published on: 10/7/2008    Last Visited: 3/17/2008  

  metastases and osteosarcoma" by Peter M. Anderson, M.D., Ph.D., a pediatric oncologist at The University of Texas MD Anderson Cancer

Page:  1 2 3 4